Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups☆
Introduction
Biliary carcinoma represents 3% of digestive cancers, and 15% of primary hepatobiliary malignancy [1]. The only potentially curative treatment for biliary carcinoma is complete surgical resection. After curative surgery, 5-year overall survival (OS) is 30–45% [2], [3]. Peritoneal metastasis (PM) is the most frequent site of metastasis for biliary carcinoma, and is present at time of diagnosis in 10–20% of patients [4]. Metachronous PM is frequent in gallbladder carcinoma, occurrence is potentially increased when there is iatrogenic gallbladder perforation during surgery [5], [6], or after transparietal biopsy [7]. For patients with biliary carcinoma, PM is associated with limited survival despite modern chemotherapy. Median OS for unresectable biliary carcinoma treated with palliative chemotherapy is 15.2 months [8]. Based on international recommendations, biliary carcinoma with PM is not considered as a resectable disease, independently of the primary tumor resectability. Standard treatment for biliary carcinoma PM is palliative chemotherapy with combination of gemcitabin and cisplatin [9].
Since 1980's, the concept of complete cytoreductive surgery (CRS), to treat macroscopic disease, combined with intraperitoneal chemotherapy, to treat microscopic residual disease, was proposed as a potentially curative treatment for PM [10], [11].
This study aimed to assess OS in patients suffering from biliary carcinoma with peritoneal metastasis (PMC) treated by CRS and HIPEC. OS was compared to patients receiving palliative chemotherapy.
Section snippets
Patient population
From a multi-center international database (collaborative database of PSOGI and BIG-RENAPE working groups), two groups were identified. The “CRS/HIPEC group” represented patient with PMC treated with CRS and HIPEC. The “systemic chemotherapy group”, represented patients with PMC initially considered resectable (without PM identified on preoperative imaging), finally not resected due to incidental discovery of PM during surgical exploration. They were subsequently treated with palliative
Patients
Thirty-four patients in the CRS/HIPEC group were compared to 21 patients in the systemic chemotherapy group.
Table 1 describes the characteristics of theses 2 groups of patient. Significant differences were observed regarding location of the primary tumor, gallbladder tumors were significantly more frequent in the CRS/HIPEC group (35% vs 19%, p = 0.001). The median peritoneal cancer index (PCI) was 9 in the CRS/HIPEC group (ranged 3 to 26). PCI was unknown in the systemic chemotherapy group.
Discussion
Here we report the largest international multi-institutional series of patients with peritoneal metastases from biliary carcinoma treated with CRS and HIPEC. The major finding of this study was a statistically significant better OS for patients who underwent macroscopically complete CRS combined with HIPEC for biliary carcinoma with PM compared to palliative chemotherapy. To the best of our knowledge, such survival results have never been reported in the management of PM from biliary carcinoma.
Conclusion
CRS and HIPEC for biliary carcinoma with PM may provide promising survival when compared to palliative chemotherapy. This is the first study suggesting that improve survival for biliary carcinoma with PM can be obtained with CRS and HIPEC. This treatment should be considered only for selected patients with good general status, low burden of disease, and PM amenable to complete CRS.
Synopsis
Complete cytoreductive surgery and HIPEC may improve long-term survival in selected patients with peritoneal metastasis from biliary carcinoma.
Conflict of interest statement
The authors report no conflicts of interest that are relevant to this article.
Acknowledgments
The authors thank Peggy Jourdan-Enfer and Anaïs Poulet for their expert help with data collection. The authors thank and Christelle Maurice and Evelyne Decullier for help with the data analysis.
References (20)
- et al.
Incidence of gastrointestinal cancers in France
Gastroenterol Clin Biol
(2004) - et al.
Transperitoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination
HBP
(2011 May) - et al.
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomized open label, non-comparative phase 2 trial
Lancet Oncol
(2014) - et al.
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database
Lancet Oncol
(2016 Dec) - et al.
Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution
Ann Surg
(2007 May) - et al.
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment
J Clin Oncol
(2011 Aug 10) - et al.
Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document
Gut
(2002) - et al.
Early gallbladder carcinoma does not warrant radical resection
Br J Surg
(2001) - et al.
Laparoscopic cholecystectomy can disseminate in situ carcinoma of the gallbladder
J Am Coll Surg
(1995) - et al.
Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis
Gastrointest Cancer Res
(2011 Sep)
Cited by (19)
Insights into synchronous peritoneal metastases from hepatobiliary origin: Incidence, risk factors, treatment, and survival from a nationwide database
2023, European Journal of Surgical OncologyCytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy vs. cytoreductive surgery alone for intrahepatic cholangiocarcinoma with peritoneal metastases: A retrospective cohort study
2021, European Journal of Surgical OncologyCitation Excerpt :A meta-analysis indicated that the addition of HIPEC to CRS and systemic therapy improved the OS of patients with epithelial ovarian carcinoma [27]. A multicenter retrospective study suggested that CRS combined with HIPEC was a feasible option for cholangiocarcinoma with peritoneal metastasis and that the survival benefit was comparable to that of palliative chemotherapy [23]. Many specialized centers used HIPEC for peritoneal carcinomatosis because of the cytotoxic effect of heat [28–30].
Cytoreductive surgery for peritoneal disease: From palliative to curative
2019, Bulletin de l'Academie Nationale de MedecineCT-based deep learning model: a novel approach to the preoperative staging in patients with peritoneal metastasis
2023, Clinical and Experimental MetastasisPIPAC for Gastrointestinal Malignancies
2023, Journal of Clinical Medicine
- ☆
All authors reviewed and edited the manuscript. All were agree with the submission.